Tscan Therapeutics has a price-to-earnings (P/E) ratio of -0.49 (TTM). This compares to an industry average of -14.44. The P/S ratio for Tscan Therapeutics is currently 7.65 (TTM). What is Tscan ...

Levered free cash flow was -14.46 million USD reflecting a 38.23% change from the previous quarter. In the most recent fiscal year, Tscan Therapeutics generated -135.32 million USD in cash from ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and ...

T2 Biosystems, Inc. engages in the development and commercialization of medical diagnostic products for critical unmet needs in the healthcare. Its products include T2Dx instrument, T2Candida panel, ...

TScan Therapeutics Inc. Annual stock financials by MarketWatch. View the latest TCRX financial statements, income statements and financial ratios.

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously ...